CSN Login
Members Online: 9

Statin use and risk of prostate cancer and high-grade prostate cancer: Results from the REDUCE study - Abstract

hopeful and opt...
Posts: 1357
Joined: Apr 2009

Statin use and risk of prostate cancer and high-grade prostate cancer: Results from the REDUCE study - Abstract

 

Background: Statins are associated with lower PSA levels.

As PSA is the primary method for prostate cancer (PC) screening, this confounds any associations between statins and risk of being diagnosed with PC. Thus, we examined the association between statins and cancer and high-grade cancer in REDUCE, where biopsies were largely PSA-independent.

Methods: Post-hoc secondary analysis of REDUCE, which was a prospective multinational randomized controlled trial of dutasteride vs placebo for 4 years among men aged 50-75 years with PSA of 2.5-10.0 ng ml-1 and a negative biopsy at baseline, and included PSA-independent biopsies mandated at 2- and 4-years. Analyses were limited to men who underwent at least one biopsy while under study (n=6729). The association between baseline statin use and risk of overall, high-grade (Gleason ≥7) or low-grade (Gleason ≤6) PC vs no cancer was examined using multinomial logistic regression adjusting for age, race, baseline PSA, prostate volume, rectal examination findings, body mass index (BMI), comorbidities, smoking, alcohol intake and treatment arm.

Results: Of 6729 men who had at least one biopsy while on study, 1174 (17.5%) were taking a statin at baseline. Men taking statins were older, had lower PSA levels, higher BMI values and lower serum testosterone and dihydrotestosterone levels, though differences, were slight. Statin use was not associated with overall PC diagnosis (multivariable OR 1.05, 95% CI 0.89-1.24, P=0.54). When stratified by grade, statin use was not associated with low-grade (multivariable OR 1.03, 95% CI 0.85-1.25, P=0.75) or high-grade cancer (multivariable OR 1.11, 95% CI 0.85-1.45, P=0.46). The major limitation is the inclusion of only men with a negative baseline biopsy.

Conclusions: Among men with a negative baseline biopsy and follow-up biopsies largely independent of PSA, statins were not associated with cancer or high-grade cancer.

Written by: 
Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, Rittmaster RS.   Are you the author? 
Surgery Section, Durham VA Medical Center, Durham, NC, USA; Duke Prostate Center, Division of Urological Surgery, Department of Surgery, Duke University School of Medicine, Durham, NC, USA; Department of Pathology, Duke University School of Medicine, Durham, NC, USA.

Reference: Prostate Cancer Prostatic Dis. 2013 Apr 9. Epub ahead of print. 
doi: 10.1038/pcan.2013.10

PubMed Abstract
PMID: 23567655

UroToday.com Prostate Cancer Section

Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2014 © Cancer Survivors Network